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iminishing Returns . . .
nd Too Many Choices . . .
he Saga of Pharmacologic
herapy to Reduce the
omplications of Percutaneous
oronary Intervention*
ichael L. Stadius, MD, FACC
eattle, Washington
omplications of percutaneous coronary intervention (PCI),
nd coronary stenting in particular, are well characterized.
eath, myocardial infarction (MI), and the need for emergent
r urgent repeat revascularization are all known possible out-
omes of PCI (1). Thrombosis is a common mechanism in the
evelopment of each of these complications (2).
See page 20
A number of pre-procedural treatment strategies using
nti-thrombotic therapies have evolved in an attempt to
ower the rate of complications related to performance of
CI. Pre-treatment with aspirin and unfractionated heparin
s the bedrock of pharmacotherapy to lower procedural risk
3). In recent years, a number of new anti-thrombotic agents
ave been tested as pre-procedural treatments in conjunc-
ion with or as substitutes for aspirin and unfractionated
eparin to minimize complications. Among these agents are
he thienopyridines, ticlopidine (4), and clopidogrel (5,6);
he platelet glycoprotein receptor IIb/IIIa inhibitors, abcix-
mab (7–9), eptifibatide (10,11), and tirofiban (12); the low
olecular weight heparins, enoxaparin (13,14), and dalte-
arin (15); and the direct thrombin inhibitor, bivalirudin
16,17). At least some clinical evidence supports the use of
ach of these agents as pre-treatment for the reduction of
hrombosis-mediated PCI complications.
Ticlopidine and clopidogrel are accepted treatments to
educe the risk of sub-acute thrombosis when started soon
fter a stenting procedure (18–21). Because of its more
avorable side effect profile, clopidogrel has become the
ccepted thienopyridine for clinical use in the post-stent
etting (22). Whether there is additional benefit in reducing
rocedural complications by starting clopidogrel before the
rocedure has been the subject of two large randomized
linded trials, the Percutaneous Coronary Intervention-
lopidogrel in Unstable angina to prevent Recurrent Events
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the VA Puget Sound Health Care System and University of Washington,teattle, Washington.PCI-CURE) (5) and the Clopidogrel for the Reduction of
vents During Observation (CREDO) (6) studies. In each
tudy, patients were randomized to double-blind treatment
ith clopidogrel or placebo before PCI and again beginning
8 days after the procedure. However, from PCI to a day
etween 14 and 28 days after the procedure, all patients
eceived open-label clopidogrel or ticlopidine because of the
nown benefit of these drugs in combination with aspirin
or prevention of sub-acute thrombosis. The primary end
oint in the PCI-CURE trial was a composite of 30-day
ardiovascular death, MI, and the need for urgent revascu-
arization; this end point was reduced by 31% in patients
ssigned to clopidogrel treatment. In the CREDO trial, the
rimary end points were the composite of death, MI, and
troke at one year and the composite of death, MI, and
rgent target vessel revascularization at 28 days. The one-
ear composite end point was significantly reduced by 27%
ith clopidogrel treatment. In order to focus on the ques-
ion of benefit of clopidogrel pre-treatment and reduction of
CI-related procedural complications, it is necessary to
valuate short-term treatment effects. In the PCI-CURE
0-day trial data, the pre-treatment benefit with clopidogrel
as limited to reduction of frequency of MI, with a trend
oward benefit in need for urgent revascularization but no
ffect at all on cardiovascular death. In the CREDO trial,
re-treatment was not associated with a statistically signif-
cant reduction in the composite end point at the 28-day
ime point, although there was a trend toward benefit (p 
.23). There were fewer events in each of the components of
he composite end point (death, MI, and urgent revascular-
zation) for pre-treated patients and an additional sub-group
nalysis looking at duration of pre-treatment indicated
enefit for clopidogrel patients if they received the drug at
east 6 h before the PCI but no benefit if 6 h elapsed
etween pre-treatment and the PCI.
We can add the study of van der Heijden et al. (23) in this
ssue of the Journal to the PCI-CURE and CREDO trial
esults. This current study used a randomized, non-blinded
esign to evaluate pre-treatment with clopidogrel in the
etting of coronary stenting. Patients randomized to pre-
reatment received 300 mg of clopidogrel three days before
he procedure followed by 75 mg per day thereafter. Patients
n the control group received 300 mg of clopidogrel imme-
iately after the procedure followed by 75 mg per day. The
re-treatment interval in the current trial falls between the
re-treatment time interval used in the PCI-CURE (me-
ian pre-treatment duration was 6 days) and the CREDO
3 to 24 h) trials. The control group of the current trial
eceived a loading dose of clopidogrel early after stenting,
nlike the control group patients in the CREDO trial, who
eceived only the daily maintenance dose of clopidogrel early
fter the PCI procedure was completed. In the PCI-CURE
rial, a loading dose strategy for clopidogrel or ticlopidine
fter PCI in the control group was not specified, only that
hese patients were treated with open-label drug for two to
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Editorial Comment July 7, 2004:25–7our weeks after the procedure. Using this study design, van der
eijden et al. (23) found no difference in the frequency of
ardiac injury marker elevation between the two treatment
roups. The current study is small in size, but there was no
bvious benefit or detriment to administering clopidogrel
efore treatment when clinical end points were assessed.
How might one categorize the sum of the available
andomized trial data regarding effectiveness of pre-
reatment with 300 mg of clopidogrel on procedural com-
lications of PCI? One approach would be to categorize the
esults of each of the three trials as either “beneficial” or “no
reatment effect” based on the overall 28- to 30-day data of
ach. This approach yields one trial being “beneficial” and
wo trials showing “no treatment effect.” The obvious
imitations of this approach are: 1) equating the small size of
an der Heijden et al trial. with the much-larger size of the
ther two trials; and 2) ignoring some of the nuances of the
esults of the two large trials. An alternate approach would
e to combine the 28- to 30-day clinical outcome results of
ll three trials. A very informal “meta-analysis” of the
ublished randomized data is as follows: (pre-treatment vs.
o pre-treatment groups) total patients, 2,467 versus 2,510;
eath, 14 (0.6%) versus 17 (0.7%); MI, 81 (3.3%) versus 111
4.4%); urgent revascularization, 35 (1.4%) versus 53 (2.1%).
hese numbers suggest to this reader a probable (in the
egalistic sense) small benefit in prevention of procedural MI
on the order of preventing 1 MI event per 100 treated
atients) and perhaps a possible small treatment effect on
he prevention of urgent revascularization. It seems very
nlikely that there is any effect on procedural death risk with
re-treatment. Thus, the answer to the initially posed
uestion appears to be that pre-treatment with clopidogrel
ields a result somewhere between the bounds of no
etectable benefit and a small treatment benefit in the
verall spectrum of clinical utility.
Recently, there has been interest in using a larger loading
ose of clopidogrel for pre-treatment, 600 mg. A study in
CI patients comparing this higher pre-treatment dose of
lopidogrel with a historical cohort of patients pre-treated
ith ticlopidine reported a lower incidence of the composite
nd point of death, MI, and urgent revascularization in
hose receiving the high-dose clopidogrel load (24). A
econd study, the Intracoronary Stenting and Antithrom-
otic Regimen Rapid Early Action for Coronary Treatment
tudy, included over 2,100 relatively low-risk patients un-
ergoing PCI; all received the high-dose (600 mg) clopi-
ogrel load before PCI and then were randomized to
bciximab treatment or placebo (25). There was no apparent
enefit to abciximab treatment being added to high loading
ose clopidogrel in this study. Unfortunately, neither of
hese studies provides us with any information about the
ncremental benefit of the high loading dose clopidogrel
egimen compared with either placebo or to the previously
tudied 300-mg loading dose regimen in the pre-treatment
CI setting.
Why clopidogrel pre-treatment fails to have a larger ienefit may be explained by several different factors. Indi-
idual patient response to clopidogrel loading and mainte-
ance dosing is variable (26,27). Between 20% and 30% of
ested healthy subjects showed no significant inhibitory
ffect on measures of platelet reactivity after clopidogrel was
tarted. There may be a genetic basis explaining the vari-
bility in individual response to clopidogrel dosing (28).
rug interactions may alter responsiveness to clopidogrel
29,30). Several recent in vitro studies of platelet reactivity
ave implicated an inhibitory effect of lipophilic 3-hydroxy-
-methylglutaryl coenzyme A reductase inhibitors on clo-
idogrel treatment effect. Clinical presentation may be
nother factor influencing treatment benefit. As van der
eijden et al. (23) note, there may be a larger treatment
ffect in patients presenting with ACS than those who have
more stable clinical presentation who present for elective
CI. Finally, the relative prevalence of complications of
CI affects the relative efficacy of clopidogrel (or any other
reatment). With 30-day major adverse event rates less than
.5% in the PCI settings being studied, the ability of any
reatment to show a large effect is diminished. Because
hrombosis most likely contributes mechanistically to only a
art of these complications, the potential benefit of any
nti-thrombotic therapy is further limited. Thus, the “re-
urn” on any new treatment offered in this setting is likely to
e diminished based the relative low frequency of the
omplications with current conventional therapy.
If clopidogrel were the only novel anti-thrombotic ther-
py for the prevention of PCI procedural complications,
hen this whole discussion would have ended in the first
aragraph because even a small treatment benefit would be
orthwhile to many interventionalists. However, the coro-
ary interventional community is literally inundated with
nti-thrombotic treatment options that are being advocated
s methods to reduce procedural complications. These
ptions (aspirin in different dosages, bolus or weight ad-
usted heparin with or without activated clotting time
onitoring, abciximab, eptifibatide, tirofiban, enoxaparin,
alteparin, bivalirudin, and clopidogrel—I suspect this list is
ot comprehensive given new drugs entering clinical testing
ll the time) leave the interventionalist with numerous
ossibilities to ponder. In the absence of well-designed,
robably very large clinical trials protected from the issues of
nancial self-interest, it seems unlikely that there will be any
nal resolution to the question: “What is the optimal
nti-thrombotic treatment regimen to minimize PCI pro-
edural complications?” For now, and probably for a long
ime, we will simply have too many choices to consider
ithout definitive studies to resolve the issue of what is best.
Clopidogrel may be a reasonable option for some inter-
entionalists as a pre-treatment in the PCI setting. Its
enefit in preventing sub-acute thrombosis when used after
tenting (18–22), in reducing cardiovascular events in pa-
ients with symptomatic atherosclerosis (31,32), and in its
ase of dosing are all important attributes that could
nfluence one toward a strategy of pre-treatment in the PCI
s
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July 7, 2004:25–7 Editorial Commentetting; but the use of clopidogrel as a pre-treatment before
CI should be balanced against the increased risk of
perative complications seen in patients receiving combined
spirin and clopidogrel compared with aspirin alone when
oronary artery bypass surgery is performed (33), an infre-
uent but known possibility for patients being considered
or PCI. Other interventionalists, however, may find one or
ore of the other pre-treatment choices having an impact
n PCI procedural risk to be more compelling in their practice
ettings. The saga of defining optimal anti-thrombotic therapy
o reduce PCI procedural risk continues.
eprint requests and correspondence: Dr. Michael L. Stadius
ardiology, S-111C VA Medical Center, 1660 South Columbian
ay, Seattle, Washington 98108. E-mail: michael.stadius@
ed.va.gov.
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